企业名称天津美科茵贸易有限公司法定代表人田小雪注册资本5000万人民币国标行业制造业>医药制造 业>化学药品制剂制造地址天津自贸试验区（东疆综合保税区）澳洲路6262号202室（东疆商秘自贸托 管13217号）企业类型有限责任公司(法人独资)营业期限2026-2-27至无固定期限登记机关中国（天津） 自由贸易试验区市场监督管理局 来源：市场资讯 经营范围含机械零件、零部件销售；五金产品零售；国内贸易代理；新能源汽车整车销售；汽车拖车、 求援、清障服务；汽车零配件零售；汽车零配件批发；电车销售；机动车修理和维护；商务代理代办服 务；互联网销售（除销售需要许可的商品）；电子产品销售；汽车装饰用品销售；信息咨询服务（不含 许可类信息咨询服务）。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 天眼查显示，近日，天津美科茵贸易有限公司成立，法定代表人为田小雪，注册资本5000万人民币，由 上海乐创达科技有限公司全资持股。 序号股东名称持股比例1上海乐创达科技有限公司100% ...

"告知承诺制"是此次改革试点的核心举措之一。根据方案，对符合条件的报告表类项目，在企业及环评 单位信用良好、材料规范并作出书面承诺的前提下，生态环境部门可不经评估、审查直接作出审批决 定，实现环评审批的"极速通关"。此举大幅压缩了审批时间，将为企业争取市场先机提供强大助力。为 确保"放得开、管得住"，方案同步建立了全覆盖的事后技术复核与严格的事中事后监管机制。 受理申请后，泰安市生态环境局开发区分局工作专班争分夺秒、并联推进。一方面，对申报材料的规范 性、承诺内容的完整性进行快速审查；另一方面，坚守生态环境质量底线，对项目产业政策符合性、选 址与环境管控要求进行严格把关。最终，在两个项目受理后最短时间内，于2月6日当天依法依规出具了 环评批复文件，抢在国债项目申报关键节点前，为企业扫清了障碍。 此次高效服务，是泰安市生态环境局开发区分局近年来持续深化审批服务机制改革成效的集中体现。泰 安市生态环境局开发区分局依托省级规划环评与项目环评联动试点，已构建起"提前介入、分类优化、 要素保障"的常态化服务体系。通过实施报告表降级管理、告知承诺制审批、污染物总量指标统筹调配 等创新举措，有效提升了服务重大项目的精准性和 ...

Core Viewpoint - Pfizer Inc. has had its application for PF-07868489 accepted by the National Medical Products Administration, indicating progress in the approval process for this therapeutic biological product [1] Group 1: Application Details - The application for PF-07868489 was accepted on January 15, 2026, with the acceptance number JXSB2600007 [1] - PF-07868489 is categorized as a therapeutic biological product and is classified as a supplementary application under registration category 1 [1] Group 2: Company Information - Pfizer Inc. was established on October 7, 1989, and is a foreign-owned limited liability company engaged in the manufacturing of chemical pharmaceutical preparations [1] - The company has a registered capital of 80.4 million USD and a paid-in capital of 80.4 million USD, with 935 employees [1] - The sole shareholder is American Wyeth Corporation, holding 100% of the shares with a contribution of 80.4 million USD, registered on November 30, 2017 [1]

Core Viewpoint - A new company, YaoXing (Shanghai) Biopharmaceutical Technology Co., Ltd., has been established with a registered capital of 20 million RMB, fully owned by Sichuan Baili Pharmaceutical Co., Ltd. [1] Company Summary - Company Name: YaoXing (Shanghai) Biopharmaceutical Technology Co., Ltd. [1] - Legal Representative: Zhu Yi [1] - Registered Capital: 20 million RMB [1] - Shareholder: Sichuan Baili Pharmaceutical Co., Ltd. holds 100% [1] - Company Type: Limited liability company (wholly owned by a natural person) [1] - Business Scope: Includes drug production, clinical trial services, drug wholesale, and import/export of drugs [1] Industry Summary - Industry Classification: Manufacturing > Pharmaceutical Manufacturing > Chemical Drug Preparation Manufacturing [1] - Address: 1st Floor, No. 14-15, Banxia Road, Pudong New District, Shanghai [1] - Business Duration: Until December 22, 2025, with no fixed term thereafter [1] - Registration Authority: Pudong New District Market Supervision Administration [1]

Core Insights - Pfizer Inc. has had its application for Sulfate Remegipant orally disintegrating tablets accepted by the National Medical Products Administration on December 17, 2025 [1] Company Overview - Pfizer Inc. was established on October 7, 1989, and is classified as a medium-sized foreign-owned limited liability company in the chemical pharmaceutical manufacturing industry [1] - The company has a registered capital of 80.4 million USD and a paid-in capital of 80.4 million USD, with 935 insured employees [1] - The sole shareholder is American Hui Zhi Enterprise Company, holding 100% of the shares with a subscribed capital contribution of 80.4 million USD, dated November 30, 2017 [1] Application Details - The application number for the drug is JXHB2500169, categorized as a chemical drug under a supplementary application with a registration classification of 2.4 [1] - The application was officially accepted on December 17, 2025 [1]

Core Viewpoint - Pfizer Inc. has had its application for PF-07275315 injection accepted by the National Medical Products Administration, indicating progress in its drug development pipeline [1] Group 1: Company Information - Pfizer Inc. was established on October 7, 1989, and is classified as a medium-sized foreign-owned limited liability company in the chemical pharmaceutical manufacturing industry [1] - The registered capital of Pfizer Inc. is 8.04 million USD, with the same amount being the paid-in capital [1] - The company has 935 insured employees and is located at 22 Daqing Road, Dalian Economic and Technological Development Zone, Liaoning Province, China [1] Group 2: Application Details - The application for PF-07275315 injection was accepted on December 16, 2025, with the acceptance number JXSL2500239 [1] - PF-07275315 is categorized as a therapeutic biological product and is classified under import registration category 1 [1] - The application is being handled by Pfizer Inc. and Pfizer (China) Research & Development Co., Ltd. [1] Group 3: Shareholder Information - The sole shareholder of Pfizer Inc. is American Huizhi Enterprise Company, holding 100% of the shares with a subscribed capital of 8.04 million USD [1] - The subscribed capital was contributed on November 30, 2017, and the first shareholding date was June 9, 2023 [1]

Core Points - The 2025 mandatory clean production audit list includes 17 enterprises in Hainan Province [1] - The industries represented include chemical pharmaceuticals, livestock slaughtering, paper manufacturing, metallurgy, traditional Chinese medicine, chemical products from forest resources, thermal power generation, biomass energy generation, and gold mining [1] - Enterprises must complete the clean production audit within specified timelines and report results on the provincial clean production management platform [1][2] Group 1 - A total of 17 enterprises have been selected for the 2025 mandatory clean production audit in Hainan Province [1] - The industries involved span various sectors, including chemical pharmaceuticals, livestock slaughtering, and energy generation [1] - Enterprises are required to publish relevant information and complete the audit process within one year [1] Group 2 - Local environmental departments are tasked with strengthening daily supervision of the clean production audits [1] - Companies must designate responsible leaders and contacts for the audit process and report this information to the provincial ecological environment department [2] - There are penalties for companies that fail to comply with the audit requirements or do not report results accurately [1]

Group 1 - The Ministry of Commerce and Jiangsu Provincial Government issued a development plan for the biopharmaceutical industry in the Jiangsu Free Trade Zone, encouraging innovative companies to raise funds through various stock exchanges and bond issuances [1] - The plan supports the establishment of sub-funds for biopharmaceutical investments and allows eligible projects to issue real estate investment trusts (REITs) [1] - In July, profits in the high-tech manufacturing sector increased by 18.9%, with significant contributions from aerospace (40.9% profit growth) and semiconductor industries, where profits grew by 176.1%, 104.5%, and 27.1% in various segments [1] Group 2 - The ChiNext Index saw a strong increase of 1.34%, with notable stock performances from Tianfu Communication (20.00% increase) and Jiejia Weichuang (18.18% increase) [3] - The ChiNext ETF Ping An reported a 4.62% increase over the past week, with a trading volume of 785.82 million yuan [3] - The ChiNext ETF Ping An has a one-year Sharpe ratio of 1.59 and a management fee of 0.15%, which is among the lowest in comparable funds [4]

Group 1 - In July, the revenue of industrial enterprises above designated size increased by 0.9% year-on-year, with total profits reaching 40,203.5 billion yuan from January to July [1] - The manufacturing sector saw a profit increase of 6.8% year-on-year in July, accelerating by 5.4 percentage points compared to June, contributing to a faster overall profit growth for industrial enterprises [1] - High-tech manufacturing played a significant role, with its profit growth accelerating the overall profit growth of industrial enterprises by 2.9 percentage points compared to June [1] Group 2 - The aerospace and equipment manufacturing industry experienced a profit growth of 40.9%, while the integrated circuit manufacturing and semiconductor device manufacturing sectors saw profits increase by 176.1% and 104.5% respectively [1] - The "Two New" policies have shown significant effectiveness, driving profit growth in various sectors, including a 87.9% increase in electronic and electrical machinery manufacturing [2] - Under the consumption upgrade policy, the computer manufacturing sector saw a profit increase of 124.2%, while smart drone manufacturing and household cleaning appliance manufacturing grew by 100.0% and 29.7% respectively [2]

Core Insights - In July, profits of large-scale industrial enterprises decreased by 1.5% year-on-year, but the decline narrowed by 2.8 percentage points compared to June, marking two consecutive months of narrowing [1][2] - High-tech manufacturing profits turned from a 0.9% decline in June to an 18.9% increase in July, significantly contributing to the overall profit growth of large-scale industrial enterprises [1][3] Group 1: Industrial Profit Trends - The operating income of large-scale industrial enterprises grew by 0.9% year-on-year in July, with a cumulative growth of 2.3% from January to July, creating favorable conditions for profit recovery [2] - The total profit of large-scale industrial enterprises from January to July was 40,203.5 billion yuan, a year-on-year decrease of 1.7%, with the decline narrowing by 0.1 percentage points compared to the first half of the year [2] - Medium and small enterprises showed significant profit improvement, with profits of medium and small enterprises turning from declines of 7.8% and 9.7% in June to increases of 1.8% and 0.5% in July, respectively [2] Group 2: Manufacturing Sector Performance - Manufacturing profits increased by 6.8% year-on-year in July, accelerating by 5.4 percentage points compared to June, contributing to a 3.6 percentage point increase in overall industrial profits [3] - The raw material manufacturing sector saw profits turn from a 5.0% decline in June to a 36.9% increase in July, with the steel and petroleum processing industries achieving profits of 18.09 billion yuan and 3.46 billion yuan, respectively [3] - High-tech manufacturing profits grew rapidly, with notable increases in the aerospace sector (40.9%) and semiconductor-related industries, including integrated circuit manufacturing (176.1%) and semiconductor device manufacturing (104.5%) [3] Group 3: Policy Impact on Profit Growth - The implementation of the "Two New" policies has led to significant profit growth in related industries, with profits in electronic and electrical machinery manufacturing increasing by 87.9% in July [4] - The "old-for-new" policy for consumer goods has driven profit increases in computer manufacturing (124.2%) and smart drone manufacturing (100.0%) [4] - Related industries such as computer peripheral equipment manufacturing and sensitive components manufacturing also saw profits rise by 57.0% and 51.9%, respectively [4]